Cargando…

Activation of PDGF Pathway Links LMNA Mutation to Dilated Cardiomyopathy

Lamin A/C (LMNA) is one of the most frequently mutated genes in dilated cardiomyopathy (DCM). LMNA-related DCM is a common inherited cardiomyopathy associated with systolic dysfunction and high prevalence arrhythmias. Here we modeled the LMNA-DCM in vitro using patient-specific induced pluripotent s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jaecheol, Termglinchan, Vittavat, Diecke, Sebastian, Itzhaki, Ilanit, Lam, Chi Keung, Garg, Priyanka, Lau, Edward, Greenhaw, Matthew, Seeger, Timon, Wu, Haodi, Zhang, Joe Z., Chen, Xingqi, Gil, Isaac Perea, Ameen, Mohamed, Sallam, Karim, Rhee, June-Wha, Churko, Jared, Chaudhary, Rinkal, Chour, Tony, Wang, Paul J., Snyder, Michael P., Chang, Howard Y, Karakikes, Ioannis, Wu, Joseph C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779479/
https://www.ncbi.nlm.nih.gov/pubmed/31316208
http://dx.doi.org/10.1038/s41586-019-1406-x
Descripción
Sumario:Lamin A/C (LMNA) is one of the most frequently mutated genes in dilated cardiomyopathy (DCM). LMNA-related DCM is a common inherited cardiomyopathy associated with systolic dysfunction and high prevalence arrhythmias. Here we modeled the LMNA-DCM in vitro using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Electrophysiological studies showed that the mutant iPSC-CMs displayed aberrant calcium homeostasis leading to arrhythmias at the single-cell level. Mechanistically, we uncovered that the platelet-derived growth factor (PDGF) signaling pathway was activated in mutant iPSC-CMs when compared to isogenic controls. Conversely, pharmacological and molecular inhibition of the PDGF signaling pathway ameliorated the arrhythmia phenotypes of mutant iPSC-CMs in vitro. Taken together, our findings suggest that the activation of the PDGF pathway contributes to the pathogenesis of the LMNA-DCM and point to PDGF receptor beta (PDGFRB) as a potential therapeutic target.